105 related articles for article (PubMed ID: 15581462)
21. Medical treatment of cholestatic liver disease.
Paumgartner G; Pusl T
Clin Liver Dis; 2008 Feb; 12(1):53-80, viii. PubMed ID: 18242497
[TBL] [Abstract][Full Text] [Related]
22. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases.
Oude Elferink RP; Paulusma CC; Groen AK
Gastroenterology; 2006 Mar; 130(3):908-25. PubMed ID: 16530529
[TBL] [Abstract][Full Text] [Related]
23. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
[TBL] [Abstract][Full Text] [Related]
24. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
25. Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR.
Liddle C; Goodwin B
Semin Liver Dis; 2002; 22(2):115-22. PubMed ID: 12016543
[TBL] [Abstract][Full Text] [Related]
26. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders.
Lee J; Boyer JL
Semin Liver Dis; 2000; 20(3):373-84. PubMed ID: 11076403
[TBL] [Abstract][Full Text] [Related]
27. Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors.
Chiang JY
Am J Physiol Gastrointest Liver Physiol; 2003 Mar; 284(3):G349-56. PubMed ID: 12576301
[TBL] [Abstract][Full Text] [Related]
28. From blood to bile: recent advances in hepatobiliary transport.
Arrese M; Accatino L
Ann Hepatol; 2002; 1(2):64-71. PubMed ID: 15115970
[TBL] [Abstract][Full Text] [Related]
29. Bile Acids in Physiology, Pathology and Pharmacology.
Marin JJ; Macias RI; Briz O; Banales JM; Monte MJ
Curr Drug Metab; 2015; 17(1):4-29. PubMed ID: 26526836
[TBL] [Abstract][Full Text] [Related]
30. Hepatobiliary ABC transporters: physiology, regulation and implications for disease.
Jonker JW; Stedman CA; Liddle C; Downes M
Front Biosci (Landmark Ed); 2009 Jun; 14(13):4904-20. PubMed ID: 19482594
[TBL] [Abstract][Full Text] [Related]
31. Bile Acids in Cholestasis and its Treatment.
Pablo Arab J; Cabrera D; Arrese M
Ann Hepatol; 2017 Nov; 16 Suppl 1():S53-S57. PubMed ID: 31196636
[TBL] [Abstract][Full Text] [Related]
32. Nuclear receptor ligands in therapy of cholestatic liver disease.
Sturm E; Wagner M; Trauner M
Front Biosci (Landmark Ed); 2009 Jan; 14(11):4299-325. PubMed ID: 19273351
[TBL] [Abstract][Full Text] [Related]
33. [The intestinal microflora and cholestatic liver diseases].
Zhu L; Xing HC
Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):325-329. PubMed ID: 31177655
[TBL] [Abstract][Full Text] [Related]
34. Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems.
Fernández-Murga ML; Petrov PD; Conde I; Castell JV; Goméz-Lechón MJ; Jover R
Food Chem Toxicol; 2018 Oct; 120():196-212. PubMed ID: 29990576
[TBL] [Abstract][Full Text] [Related]
35. Bile formation and secretion: An update.
Boyer JL; Soroka CJ
J Hepatol; 2021 Jul; 75(1):190-201. PubMed ID: 33617926
[TBL] [Abstract][Full Text] [Related]
36. Localization status of hepatocellular transporters in cholestasis.
Crocenzi FA; Zucchetti AE; Boaglio AC; Barosso IR; Sanchez Pozzi EJ; Mottino AD; Roma MG
Front Biosci (Landmark Ed); 2012 Jan; 17(4):1201-18. PubMed ID: 22201798
[TBL] [Abstract][Full Text] [Related]
37. The Role of Bile Acids in the Human Body and in the Development of Diseases.
Shulpekova Y; Zharkova M; Tkachenko P; Tikhonov I; Stepanov A; Synitsyna A; Izotov A; Butkova T; Shulpekova N; Lapina N; Nechaev V; Kardasheva S; Okhlobystin A; Ivashkin V
Molecules; 2022 May; 27(11):. PubMed ID: 35684337
[TBL] [Abstract][Full Text] [Related]
38. Hepatobiliary membrane transporters in primary biliary cirrhosis.
Takeyama Y; Sakisaka S
Hepatol Res; 2012 Feb; 42(2):120-30. PubMed ID: 22175826
[TBL] [Abstract][Full Text] [Related]
39. Cholangiocyte biology.
Tietz PS; LaRusso NF
Curr Opin Gastroenterol; 2005 May; 21(3):337-43. PubMed ID: 15818155
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery.
Wei S; Ma X; Zhao Y
Front Pharmacol; 2020; 11():1084. PubMed ID: 32765278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
